Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$8.84 USD

8.84
2,056,947

+0.40 (4.74%)

Updated May 1, 2024 04:00 PM ET

After-Market: $8.84 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Theravance, Mylan Report Positive Data on COPD Drug Yupelri

by Zacks Equity Research

Theravance (TBPH) and partner Mylan post positive data from a late-stage program on COPD Drug, Yupelri.

    Theravance Bio (TBPH) Up 2.6% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Theravance Biopharma (TBPH) Q2 Loss Narrows, Shares Up

      by Zacks Equity Research

      Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q2. Sales beat estimates.

        Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

        by Zacks Equity Research

        Theravance Bio (TBPH) delivered earnings and revenue surprises of 38.71% and 135.40%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

          Theravance Biopharma (TBPH) Down 1.9% Since Earnings Report: Can It Rebound?

          by Zacks Equity Research

          Theravance Biopharma (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

            by Zacks Equity Research

            Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.

              Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y

              by Zacks Equity Research

              Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q1. Revenues surge year over year on increasing sales of Vibativ and collaborative revenues.

                Theravance Biopharma (TBPH) Down 7.7% Since Earnings Report: Can It Rebound?

                by Zacks Equity Research

                Theravance Biopharma (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y

                  by Zacks Equity Research

                  Theravance Biopharma (TBPH) reports wider-than-expected loss in Q4. Revenues tumble year over year on declined sales of the company's sole marketed product, Vibativ.

                    Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

                    by Zacks Equity Research

                    Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.

                      Debapriya Chakraborty headshot

                      Theravance's NDA for COPD Candidate Gets FDA Acceptance

                      by Debapriya Chakraborty

                      The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.

                        Theravance Shares Rise on Approval of Glaxo's COPD Therapy

                        by Zacks Equity Research

                        Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.

                          Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

                          by Zacks Equity Research

                          Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.

                            Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin

                            by Zacks Equity Research

                            Theravance (TBPH) submits the NDA for its key candidate, revefenacin, to the FDA for treating adults with chronic obstructive pulmonary disease.

                              Theravance (TBPH) Down 5.8% Since Earnings Report: Can It Rebound?

                              by Zacks Equity Research

                              Theravance (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                Novartis (NVS) Reports Positive Data on Ultibro Breezhaler

                                by Zacks Equity Research

                                Novartis AG (NVS) announced positive data from the FLAME study on COPD drug, Ultibro Breezhaler.

                                  Theravance/Mylan Presents Phase III Data on COPD Candidate

                                  by Zacks Equity Research

                                  Theravance Biopharma, Inc. (TBPH) and partner Mylan recently announced the presentation of additional efficacy and safety data from two pivotal phase III studies evaluating its key pipeline candidate, revefenacin (TD-4208).

                                    Theravance (TBPH) Up 17.5% Since Earnings Report: Can It Continue?

                                    by Zacks Equity Research

                                    Theravance (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                      Theravance (TBPH) Q4 Loss Wider than Expected, Revenues Beat

                                      by Zacks Equity Research

                                      Theravance Biopharma, Inc. (TBPH) reported fourth-quarter 2016 loss of $1.36 per share, much wider than both the Zacks Consensus Estimate of a loss of $1.07 and the year-ago loss of $1.23.

                                        Theravance's Infection Drug Vibativ Positive in TOUR Study

                                        by Zacks Equity Research

                                        Theravance Biopharma, Inc. (TBPH) recently released positive interim data from the ongoing TOURstudy evaluating how Vibativ (telavancin) is used to treat patients with bacteremia or infective endocarditis (IE).

                                          The Zacks Analyst Blog Highlights: ELEMENTS SPECTRUM Large Cap U.S. Sector Momentum Index ETN, Advanced Micro Devices, AK Steel Holdings, Theravance Biopharma and Fairmount Santrol Holdings

                                          by Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: ELEMENTS SPECTRUM Large Cap U.S. Sector Momentum Index ETN, Advanced Micro Devices, AK Steel Holdings, Theravance Biopharma and Fairmount Santrol Holdings

                                            Sweta Killa headshot

                                            Santa on Way to Take Over Trump Rally? ETFs & Stocks to Buy

                                            by Sweta Killa

                                            Given the encouraging macro trends and investors' increased appetite for riskier assets, Santa seems to be coming to the stock market this year.

                                              Theravance Stock Up on Fast Track Status for Velusetrag

                                              by Zacks Equity Research

                                              Theravance (TBPH) received Fast Track status from the FDA for velusetrag for idiopathic and diabetic gastroparesis.